139 results on '"Yokoyama, Seiya"'
Search Results
2. “Surface epithelial slackening” pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype
- Author
-
Kitazono, Ikumi, Akahane, Toshiaki, Yokoyama, Seiya, Kobayashi, Yusuke, Togami, Shinichi, Yanazume, Shintaro, Tasaki, Takashi, Noguchi, Hirotsugu, Tabata, Kazuhiro, Kobayashi, Hiroaki, and Tanimoto, Akihide
- Published
- 2023
- Full Text
- View/download PDF
3. Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis
- Author
-
Kirishima, Mari, Yokoyama, Seiya, Matsuo, Kei, Hamada, Taiji, Shimokawa, Michiko, Akahane, Toshiaki, Sugimoto, Tomoyuki, Tsurumaru, Hirohito, Ishibashi, Matsujiro, Mataki, Yuko, Ootsuka, Takao, Nomoto, Mitsuharu, Hayashi, Chihiro, Horiguchi, Akihiko, Higashi, Michiyo, and Tanimoto, Akihide
- Published
- 2022
- Full Text
- View/download PDF
4. An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors
- Author
-
Hamada, Taiji, Akahane, Toshiaki, Yokoyama, Seiya, Higa, Nayuta, Kirishima, Mari, Matsuo, Kei, Shimokawa, Michiko, Yoshimoto, Koji, and Tanimoto, Akihide
- Published
- 2022
- Full Text
- View/download PDF
5. PCP4/PEP19 downregulates neurite outgrowth via transcriptional regulation of Ascl1 and NeuroD1 expression in human neuroblastoma M17 cells
- Author
-
Kitazono, Ikumi, Hamada, Taiji, Yoshimura, Takuya, Kirishima, Mari, Yokoyama, Seiya, Akahane, Toshiaki, and Tanimoto, Akihide
- Published
- 2020
- Full Text
- View/download PDF
6. Exercise Suppresses Head and Neck Squamous Cell Carcinoma Growth via Oncostatin M.
- Author
-
Yoshimura, Takuya, Hirano, Yuka, Hamada, Taiji, Yokoyama, Seiya, Suzuki, Hajime, Takayama, Hirotaka, Migita, Hirono, Ishida, Takayuki, Nakamura, Yasunori, Ohsawa, Masahiro, Asakawa, Akihiro, Ishihata, Kiyohide, and Tanimoto, Akihide
- Subjects
SQUAMOUS cell carcinoma ,SURVIVAL ,MOUTH tumors ,RESEARCH funding ,EXERCISE therapy ,HEAD & neck cancer ,ENZYME-linked immunosorbent assay ,CELL proliferation ,METASTASIS ,ANIMAL experimentation ,CYTOKINES ,CELL survival ,DISEASE progression ,MYOKINES ,SARCOPENIA - Abstract
Simple Summary: In recent years, much research has focused on how exercise improves cancer prognosis and how the protein myokine, which is associated with exercise, inhibits cancer progression. However, there have been few detailed studies on oral cancer. This study is the first to show that exercise inhibits the progression of oral cancer. While other studies have shown that exercise suppresses growth, decreases the tumor formation rate, or improves survival in patients with other organ cancers, this study showed that exercise inhibits tumor formation and growth in oral cancer and prolongs survival. Furthermore, while many studies have demonstrated an indirect immune-mediated mechanism by which exercise suppresses cancer, this study suggests the additional possibility that myokines released by exercise directly affect oral cancer cells. This study has the above novelties. Major advances have been made in cancer treatment, but the prognosis for elderly cancer patients with sarcopenia and frailty remains poor. Myokines, which are thought to exert preventive effects against sarcopenia, have been reported to be associated with the prognosis of various cancers, but their effect on head and neck squamous cell carcinoma (HNSCC) is unknown. The aim of this study was to clarify the influence of exercise on the control of HNSCC and to examine the underlying mechanism involved. Mice were injected with HSC-3-M3 cells, a human cell line of highly metastatic and poorly differentiated tongue cancer, at the beginning of the study. Just prior to transplantation, blood was collected from the mice, and the levels of myokines were measured by ELISA. Oncostatin M (OSM), a selected myokine, was added to HSC-3-M3 cells, after which the cell proliferation ability, cell cycle, and protein expression were analyzed in vitro. Tumor cell viability was lower (control: 100%, exercise: 75%), tumors were smaller (control: 26.2 mm
3 , exercise: 6.4 mm3 ), and survival was longer in the exercise group than in the control group in vivo. OSM inhibited HSC-3-M3 cell proliferation in a concentration-dependent manner in vitro. The addition of OSM increased the proportion of cells in the G0/G1 phase, decreased the proportion of cells in the G2/M phase, and increased the expression of the CDK inhibitors p21 and p27. These results indicate that exercise may directly inhibit the proliferation of HNSCC cell lines via OSM. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
7. Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1
- Author
-
Matsuda, Atsushi, Higashi, Michiyo, Nakagawa, Tomomi, Yokoyama, Seiya, Kuno, Atsushi, Yonezawa, Suguru, and Narimatsu, Hisashi
- Published
- 2017
- Full Text
- View/download PDF
8. Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens
- Author
-
Akahane, Toshiaki, Kitazono, Ikumi, Yanazume, Shintaro, Kamio, Masaki, Togami, Shinichi, Sakamoto, Ippei, Nohara, Sachio, Yokoyama, Seiya, Kobayashi, Hiroaki, Hiraki, Tsubasa, Suzuki, Shinsuke, Ueno, Shinichi, and Tanimoto, Akihide
- Published
- 2020
- Full Text
- View/download PDF
9. Identification of Neck Lymph Node Metastasis-Specific microRNA—Implication for Use in Monitoring or Prediction of Neck Lymph Node Metastasis.
- Author
-
Higashi, Yutaro, Nakamura, Kodai, Takaoka, Ryota, Tani, Mika, Noma, Yusaku, Mori, Kazuki, Yamashiro, Kota, Yokoyama, Seiya, Hamada, Tomofumi, and Sugiura, Tsuyoshi
- Subjects
HEAD & neck cancer diagnosis ,METASTASIS ,LYMPH nodes ,MICRORNA ,HEAD & neck cancer ,REGRESSION analysis ,CANCER patients ,COMPARATIVE studies ,DESCRIPTIVE statistics ,RESEARCH funding ,TUMOR markers ,POLYMERASE chain reaction ,SENSITIVITY & specificity (Statistics) ,SQUAMOUS cell carcinoma - Abstract
Simple Summary: There are no established biomarkers for oral squamous cell carcinoma (OSCC), and detection of neck lymph node metastases relies on imaging studies. Diagnosis and prediction using biomarkers, which are less invasive and simpler than imaging tests, could improve prognosis if lymph node metastases could be treated earlier. In this study, serum microRNAs were successfully used to diagnose primary neck lymph node metastases and predict late neck lymph node metastases. They reflected the presence of lymph node metastasis more accurately than serum squamous cell carcinoma antigens or pathological factors. MicroRNAs (miRNAs) have attracted attention as non-invasive cancer biomarkers in various cancers; however, they have not been adequately investigated in oral squamous cell carcinoma (OSCC). This study investigated the diagnostic performance of serum-derived miRNAs at initial diagnosis for primary neck lymph node metastasis and the predictive performance for late neck lymph node metastasis based on long-term (up to approximately 8 years) follow-up of patients with OSCC. The expression of miRNAs in 40 patients with OSCC was quantified using real-time PCR (qPCR), and a comprehensive statistical analysis of the correlation of miRNA expression for primary and late neck lymph node metastases was performed. For the diagnosis of primary neck lymph node metastases, miR-423 and miR-125 were accurate. The miRNA index for primary metastasis diagnosis (miR-PM) calculated by regression analysis showed high diagnostic accuracy. The miR-5100 was useful for predicting late neck lymph node metastases. The miRNA index for late metastasis prediction (miR-LM) calculated using regression analysis showed high prediction accuracy. MiRNAs were useful for diagnosing primary neck lymph node metastases in OSCC and predicting late neck lymph node metastases. It may help to consider individualized treatment, including follow-up, surgical methods, and postoperative management. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor.
- Author
-
Yoshino, Hirofumi, Yokoyama, Seiya, Tamai, Motoki, Okamura, Shunsuke, Iizasa, Sayaka, Sakaguchi, Takashi, Osako, Yoichi, Inoguchi, Satoru, Matsushita, Ryosuke, Yamada, Yasutoshi, Nakagawa, Masayuki, Tatarano, Shuichi, Tanimoto, Akihide, and Enokida, Hideki
- Subjects
CISPLATIN ,BLADDER cancer ,RNA sequencing ,CANCER cells ,URODYNAMICS ,DRUG resistance - Abstract
Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine‐resistant and cisplatin‐resistant BCs do not exhibit cross‐resistance, and that these BCs exhibit different mRNA patterns, as revealed using RNA sequence analysis. To overcome drug resistance, we used the newly developed pan‐RAS inhibitor Compound 3144. Compound 3144 inhibited cell viability through suppression of RAS‐dependent signaling in gemcitabine‐ and cisplatin‐resistant BCs. RNA sequencing revealed that several genes and pathways, particularly those related to the cell cycle, were significantly downregulated in Compound 3144‐treated BCs. These findings provide insights into potential therapeutic strategies for treating BC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Genome Editing Using Cas9 Ribonucleoprotein Is Effective for Introducing PDGFRA Variant in Cultured Human Glioblastoma Cell Lines.
- Author
-
Hamada, Taiji, Yokoyama, Seiya, Akahane, Toshiaki, Matsuo, Kei, and Tanimoto, Akihide
- Subjects
- *
GENOME editing , *CRISPRS , *CELL lines , *PLASMIDS , *PLATELET-derived growth factor receptors , *CANCER cell analysis - Abstract
Many variants of uncertain significance (VUS) have been detected in clinical cancer cases using next-generation sequencing-based cancer gene panel analysis. One strategy for the elucidation of VUS is the functional analysis of cultured cancer cell lines that harbor targeted gene variants using genome editing. Genome editing is a powerful tool for creating desired gene alterations in cultured cancer cell lines. However, the efficiency of genome editing varies substantially among cell lines of interest. We performed comparative studies to determine the optimal editing conditions for the introduction of platelet-derived growth factor receptor alpha (PDGFRA) variants in human glioblastoma multiforme (GBM) cell lines. After monitoring the copy numbers of PDGFRA and the expression level of the PDGFRα protein, four GBM cell lines (U-251 MG, KNS-42, SF126, and YKG-1 cells) were selected for the study. To compare the editing efficiency in these GBM cell lines, the modes of clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) delivery (plasmid vs. ribonucleoprotein (RNP)), methods of transfection (lipofection vs. electroporation), and usefulness of cell sorting were then evaluated. Herein, we demonstrated that electroporation-mediated transfer of Cas9 with single-guide RNA (Cas9 RNP complex) could sufficiently edit a target nucleotide substitution, irrespective of cell sorting. As the Cas9 RNP complex method showed a higher editing efficiency than the Cas9 plasmid lipofection method, it was the optimal method for single-nucleotide editing in human GBM cell lines under our experimental conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Favorable prognostic impact of phosphatase and tensin homolog alterations in wild-type isocitrate dehydrogenase and telomerase reverse transcriptase promoter glioblastoma.
- Author
-
Higa, Nayuta, Akahane, Toshiaki, Yokoyama, Seiya, Makino, Ryutaro, Yonezawa, Hajime, Uchida, Hiroyuki, Takajo, Tomoko, Kirishima, Mari, Hamada, Taiji, Noguchi, Naoki, Otsuji, Ryosuke, Kuga, Daisuke, Nagasaka, Shohei, Yamahata, Hitoshi, Yamamoto, Junkoh, Yoshimoto, Koji, Tanimoto, Akihide, and Hanaya, Ryosuke
- Published
- 2023
- Full Text
- View/download PDF
13. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH‐wildtype glioblastoma.
- Author
-
Higa, Nayuta, Akahane, Toshiaki, Hamada, Taiji, Yonezawa, Hajime, Uchida, Hiroyuki, Makino, Ryutaro, Watanabe, Shoji, Takajo, Tomoko, Yokoyama, Seiya, Kirishima, Mari, Matsuo, Kei, Fujio, Shingo, Hanaya, Ryosuke, Tanimoto, Akihide, and Yoshimoto, Koji
- Subjects
EPIDERMAL growth factor receptors ,PROGNOSIS ,ISOCITRATE dehydrogenase ,GLIOBLASTOMA multiforme - Abstract
Background: We aimed to evaluate the mutation profile, transcriptional variants, and prognostic impact of the epidermal growth factor receptor (EGFR) gene in isocitrate dehydrogenase (IDH)‐wildtype glioblastomas (GBMs). Methods: We sequenced EGFR, evaluated the EGFR splicing profile using a next‐generation sequencing oncopanel, and analyzed the outcomes in 138 grade IV IDH‐wildtype GBM cases. Results: EGFR mutations were observed in 10% of GBMs. A total of 23.9% of the GBMs showed EGFR amplification. Moreover, 25% of the EGFR mutations occurred in the kinase domain. Notably, EGFR alterations were a predictor of good prognosis (p = 0.035). GBM with EGFR alterations was associated with higher Karnofsky Performance Scale scores (p = 0.014) and lower Ki‐67 scores (p = 0.005) than GBM without EGFR alterations. EGFRvIII positivity was detected in 21% of EGFR‐amplified GBMs. We identified two other EGFR variants in GBM cases with deletions of exons 6–7 (Δe 6–7) and exons 2–14 (Δe 2–14). In one case, the initial EGFRvIII mutation transformed into an EGFR Δe 2–14 mutation during recurrence. Conclusions: We found that the EGFR gene profiles of GBM differ among cohorts and that EGFR alterations are good prognostic markers of overall survival in patients with IDH‐wildtype GBM. Additionally, we identified rare EGFR variants with longitudinal and temporal transformations of EGFRvIII. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Two autopsy cases of severe fever with thrombocytopenia syndrome (SFTS) in Japan: A pathognomonic histological feature and unique complication of SFTS
- Author
-
Hiraki, Tsubasa, Yoshimitsu, Makoto, Suzuki, Tadaki, Goto, Yuko, Higashi, Michiyo, Yokoyama, Seiya, Tabuchi, Tomohisa, Futatsuki, Takahiro, Nakamura, Kentaro, Hasegawa, Hideki, Saijo, Masayuki, Kakihana, Yasuyuki, Arima, Naomichi, and Yonezawa, Suguru
- Published
- 2014
- Full Text
- View/download PDF
15. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach
- Author
-
Yonezawa, Suguru, Kitajima, Shinichi, Higashi, Michiyo, Osako, Masahiko, Horinouchi, Michiko, Yokoyama, Seiya, Kitamoto, Sho, Yamada, Norishige, Tamura, Yukihiro, Shimizu, Takeshi, Tabata, Mineo, and Goto, Masamichi
- Published
- 2012
- Full Text
- View/download PDF
16. Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells
- Author
-
Yamada, Norishige, Nishida, Yukari, Yokoyama, Seiya, Tsutsumida, Hideaki, Houjou, Izumi, Kitamoto, Sho, Goto, Masamichi, Higashi, Michiyo, and Yonezawa, Suguru
- Published
- 2010
- Full Text
- View/download PDF
17. Significance of mucin expression in pancreatobiliary neoplasms
- Author
-
Yonezawa, Suguru, Higashi, Michiyo, Yamada, Norishige, Yokoyama, Seiya, and Goto, Masamichi
- Published
- 2010
- Full Text
- View/download PDF
18. Aberrant DNA Methylation of Tumor-Related Genes In Oral Rinse: A Noninvasive Method for Detection of Oral Squamous Cell Carcinoma
- Author
-
Nagata, Satoshi, Hamada, Tomofumi, Yamada, Norishige, Yokoyama, Seiya, Kitamoto, Sho, Kanmura, Yuji, Nomura, Masahiro, Kamikawa, Yoshiaki, Yonezawa, Suguru, and Sugihara, Kazumasa
- Published
- 2012
- Full Text
- View/download PDF
19. Mucins in human neoplasms: Clinical pathology, gene expression and diagnostic application
- Author
-
Yonezawa, Suguru, Higashi, Michiyo, Yamada, Norishige, Yokoyama, Seiya, Kitamoto, Sho, Kitajima, Shinichi, and Goto, Masamichi
- Published
- 2011
- Full Text
- View/download PDF
20. DNA methylation and histone H3-K9 modifications contribute to MUC17 expression
- Author
-
Kitamoto, Sho, Yamada, Norishige, Yokoyama, Seiya, Houjou, Izumi, Higashi, Michiyo, Goto, Masamichi, Batra, Surinder K., and Yonezawa, Suguru
- Published
- 2011
- Full Text
- View/download PDF
21. Purification, characterization, and sequencing of antimicrobial peptides, Cy-AMP1, Cy-AMP2, and Cy-AMP3, from the Cycad (Cycas revoluta) seeds
- Author
-
Yokoyama, Seiya, Kato, Kouji, Koba, Atsuko, Minami, Yuji, Watanabe, Keiichi, and Yagi, Fumio
- Published
- 2008
- Full Text
- View/download PDF
22. The application of methylation specific electrophoresis (MSE) to DNA methylation analysis of the 5' CpG island of mucin in cancer cells
- Author
-
Yokoyama Seiya, Kitamoto Sho, Yamada Norishige, Houjou Izumi, Sugai Tamotsu, Nakamura Shin-ichi, Arisaka Yoshifumi, Takaori Kyoichi, Higashi Michiyo, and Yonezawa Suguru
- Subjects
DNA methylation pattern ,Epigenetics ,Mucin ,Colonic crypt ,Pancreatic juice ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Methylation of CpG sites in genomic DNA plays an important role in gene regulation and especially in gene silencing. We have reported mechanisms of epigenetic regulation for expression of mucins, which are markers of malignancy potential and early detection of human neoplasms. Epigenetic changes in promoter regions appear to be the first step in expression of mucins. Thus, detection of promoter methylation status is important for early diagnosis of cancer, monitoring of tumor behavior, and evaluating the response of tumors to targeted therapy. However, conventional analytical methods for DNA methylation require a large amount of DNA and have low sensitivity. Methods Here, we report a modified version of the bisulfite-DGGE (denaturing gradient gel electrophoresis) using a nested PCR approach. We designated this method as methylation specific electrophoresis (MSE). The MSE method is comprised of the following steps: (a) bisulfite treatment of genomic DNA, (b) amplification of the target DNA by a nested PCR approach and (c) applying to DGGE. To examine whether the MSE method is able to analyze DNA methylation of mucin genes in various samples, we apply it to DNA obtained from state cell lines, ethanol-fixed colonic crypts and human pancreatic juices. Result The MSE method greatly decreases the amount of input DNA. The lower detection limit for distinguishing different methylation status is < 0.1% and the detectable minimum amount of DNA is 20 pg, which can be obtained from only a few cells. We also show that MSE can be used for analysis of challenging samples such as human isolated colonic crypts or human pancreatic juices, from which only a small amount of DNA can be extracted. Conclusions The MSE method can provide a qualitative information of methylated sequence profile. The MSE method allows sensitive and specific analysis of the DNA methylation pattern of almost any block of multiple CpG sites. The MSE method can be applied to analysis of DNA methylation status in many different clinical samples, and this may facilitate identification of new risk markers.
- Published
- 2012
- Full Text
- View/download PDF
23. A tailored next‐generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
- Author
-
Higa, Nayuta, Akahane, Toshiaki, Yokoyama, Seiya, Yonezawa, Hajime, Uchida, Hiroyuki, Takajo, Tomoko, Kirishima, Mari, Hamada, Taiji, Matsuo, Kei, Fujio, Shingo, Hanada, Tomoko, Hosoyama, Hiroshi, Yonenaga, Masanori, Sakamoto, Akihisa, Hiraki, Tsubasa, Tanimoto, Akihide, and Yoshimoto, Koji
- Abstract
Central nervous system tumors are classified based on an integrated diagnosis combining histology and molecular characteristics, including IDH1/2 and H3‐K27M mutations, as well as 1p/19q codeletion. Here, we aimed to develop and assess the feasibility of a glioma‐tailored 48‐gene next‐generation sequencing (NGS) panel for integrated glioma diagnosis. We designed a glioma‐tailored 48‐gene NGS panel for detecting 1p/19q codeletion and mutations in IDH1/2, TP53, PTEN, PDGFRA, NF1, RB1, CDKN2A/B, CDK4, and the TERT promoter (TERTp). We analyzed 106 glioma patients (grade II: 19 cases, grade III: 23 cases, grade IV: 64 cases) using this system. The 1p/19q codeletion was detected precisely in oligodendroglial tumors using our NGS panel. In a cohort of 64 grade Ⅳ gliomas, we identified 56 IDH‐wildtype glioblastomas. Within these IDH‐wildtype glioblastomas, 33 samples (58.9%) showed a mutation in TERTp. Notably, PDGFRA mutations and their amplification were more commonly seen in TERTp‐wildtype glioblastomas (43%) than in TERTp‐mutant glioblastomas (6%) (P =.001). Hierarchical molecular classification of IDH‐wildtype glioblastomas revealed 3 distinct groups of IDH‐wildtype glioblastomas. One major cluster was characterized by mutations in PDGFRA, amplification of CDK4 and PDGFRA, homozygous deletion of CDKN2A/B, and absence of TERTp mutations. This cluster was significantly associated with older age (P =.021), higher Ki‐67 score (P =.007), poor prognosis (P =.012), and a periventricular tumor location. We report the development of a glioma‐tailored NGS panel for detecting 1p/19q codeletion and driver gene mutations on a single platform. Our panel identified distinct subtypes of IDH‐ and TERTp‐wildtype glioblastomas with frequent PDGFRA alterations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Significant photoresponsivity enhancement of polycrystalline BaSi2 films formed on heated Si(111) substrates by sputtering
- Author
-
Matsuno, Satoshi, Takabe, Ryota, Yokoyama, Seiya, Toko, Kaoru, Mesuda, Masami, Kuramochi, Hideto, and Suemasu, Takashi
- Abstract
We fabricated approximately 200-nm-thick BaSi2 films on Si(111) substrates at 600 °C. The formation of BaSi2 was demonstrated by X-ray diffraction and Raman spectroscopy. A reduction in the electron concentration (n = 2 × 1016 cm−3) by 3 orders of magnitude compared to that previously reported (n = 7 × 1019 cm−3) and resultant photoresponsivity enhancement by more than two orders of magnitude were achieved. The photoresponsivity increased with the bias voltage V bias applied between the top and bottom electrodes, and reached approximately 0.19 A/W at 2.0 eV, room temperature, and |V bias| = 0.5 V.
- Published
- 2018
25. Comprehensive validation of liquid-based cytology specimens for next-generation sequencing in cancer genome analysis.
- Author
-
Akahane, Toshiaki, Yamaguchi, Tomomi, Kato, Yasutaka, Yokoyama, Seiya, Hamada, Taiji, Nishida, Yukari, Higashi, Michiyo, Nishihara, Hiroshi, Suzuki, Shinsuke, Ueno, Shinichi, and Tanimoto, Akihide
- Subjects
DNA ,CYTOLOGY ,NUCLEIC acid isolation methods ,NUCLEOTIDE sequencing ,PANEL analysis - Abstract
In addition to conventional cytology, liquid-based cytology (LBC) is also used for immunocytochemistry and gene analysis. However, an appropriate method to obtain high quality DNA for next-generation sequencing (NGS) using LBC specimens remains controversial. We determined the optimal conditions for fixation with an alcohol-based fixative for LBC and DNA extraction using cultured cancer cell lines and clinical specimens. The extracted DNA was processed for NGS after the DNA quality was confirmed based on the DNA concentration and degree of degradation. The optimal conditions for cultured cells to obtain high quality DNA were to fix the cells at a density of 6 × 10
3 or 2 × 104 cells/mL and to use the magnetic bead-based DNA extraction method. Even after storing the fixed cells for 90 days, DNA extracted using the above and other extraction kits, including membrane-based methods, did not undergo degradation. Furthermore, 5-year-old residual LBC samples demonstrated high DNA quality that was suitable for NGS. Furthermore, a cancer genome panel analysis was successfully performed with DNA extracted from cultured cells fixed at 6 × 103 cells/mL for 90 days, and with DNA from residual LBC samples even after 1 year of storage. Residual LBC samples may be a useful source of DNA for clinical NGS to promote genome-based cancer medicine. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
26. The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma.
- Author
-
Guo, Xin, Noguchi, Hirotsugu, Ishii, Naoki, Homma, Takujiro, Hamada, Taiji, Hiraki, Tsubasa, Zhang, Jing, Matsuo, Kei, Yokoyama, Seiya, Ishibashi, Hiroaki, Fukushige, Tomoko, Kanekura, Takuro, Fujii, Junichi, Uramoto, Hidetaka, Tanimoto, Akihide, and Yamada, Sohsuke
- Published
- 2019
- Full Text
- View/download PDF
27. Erratum: Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1
- Author
-
Matsuda, Atsushi, Higashi, Michiyo, Nakagawa, Tomomi, Yokoyama, Seiya, Kuno, Atsushi, Yonezawa, Suguru, and Narimatsu, Hisashi
- Published
- 2017
- Full Text
- View/download PDF
28. A Comprehensive Expression Analysis of Mucins in Appendiceal Carcinoma in a Multicenter Study: MUC3 Is a Novel Prognostic Factor.
- Author
-
Shibahara, Hiroaki, Higashi, Michiyo, Yokoyama, Seiya, Rousseau, Karine, Kitazono, Iwao, Osako, Masahiko, Shirahama, Hiroshi, Tashiro, Yukie, Kurumiya, Yasuhiro, Narita, Michihiko, Kuze, Shingo, Hasagawa, Hiroshi, Kato, Takehito, Kubota, Hitoshi, Suzuki, Hideaki, Arai, Toshiyuki, Sakai, Yu, Yuasa, Norihiro, Fujino, Masahiko, and Kondo, Shinji
- Subjects
APPENDIX (Anatomy) ,MUCIN genetics ,COLON cancer prognosis ,GENE expression ,IMMUNOHISTOCHEMISTRY ,CANCER invasiveness ,CLINICAL pathology ,CANCER - Abstract
Background: Mucins are implicated in survival in various cancers, but there have been no report addressed on survival in appendiceal carcinoma, an uncommon disease with different clinical and pathological features from those of other colon cancers. We aimed to investigate the clinical implications of expression of mucins in appendiceal carcinoma. Methods: Expression profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6, MUC16 and MUC17 in cancer tissue were examined by immunohistochemistry in 108 cases of surgically resected appendiceal carcinoma. Results: The following relationships of mucins with clinicopathologic factors were identified: MUC1 with positive lymphatic invasion (p = 0.036); MUC2 with histological type (mucinous carcinoma, p<0.001), superficial invasion depth (p = 0.007), negative venous invasion (p = 0.003), and curative resection (p = 0.019); MUC3 with non-curative resection (p = 0.017); MUC5AC with histological type (mucinous carcinoma, p = 0.002), negative lymphatic invasion (p = 0.021), and negative venous invasion (p = 0.022); and MUC16 with positive lymph node metastasis (p = 0.035), positive venous invasion (p<0.05), and non-curative resection (p = 0.035). A poor prognosis was related to positive lymph node metastasis (p = 0.04), positive lymphatic invasion (p = 0.02), positive venous invasion (p<0.001), non-curative resection (p<0.001), and positive expression of MUC3 (p = 0.004). In multivariate analysis, positive venous invasion (HR: 6.93, 95% CI: 1.93–24.96, p = 0.003), non-curative resection (HR: 10.19, 95% CI: 3.05–34.07, p<0.001) and positive MUC3 expression (HR: 3.37, 95% CI: 1.13–10.03, p = 0.03) were identified as significant independent prognostic factors in patients with appendiceal carcinoma. Conclusions: Expression of MUC3 in appendiceal carcinoma is an independent factor for poor prognosis and a useful predictor of outcome in patients with appendiceal carcinoma after surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. A rare case of internal jugular vein aneurysm with massive hemorrhage in neurofibromatosis type 1
- Author
-
Hiraki, Tsubasa, Higashi, Michiyo, Goto, Yuko, Kitazono, Ikumi, Yokoyama, Seiya, Iuchi, Hiroyuki, Nagano, Hiromi, Tanimoto, Akihide, and Yonezawa, Suguru
- Published
- 2014
- Full Text
- View/download PDF
30. Diagnosis of Pancreatic Neoplasms Using a Novel Method of DNA Methylation Analysis of Mucin Expression in Pancreatic Juice.
- Author
-
Yokoyama, Seiya, Kitamoto, Sho, Higashi, Michiyo, Goto, Yuko, Hara, Taro, Ikebe, Dai, Yamaguchi, Taketo, Arisaka, Yoshifumi, Niihara, Toru, Nishimata, Hiroto, Tanaka, Sadao, Takaori, Kyoichi, Batra, Surinder K., and Yonezawa, Suguru
- Subjects
- *
DNA methylation , *PANCREATIC secretions , *PANCREATIC tumors , *MUCINS , *CARCINOGENESIS , *IMMUNOHISTOCHEMISTRY - Abstract
Mucins (MUC) play crucial roles in carcinogenesis and tumor invasion in pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasms (IPMNs). Our immunohistochemistry (IHC) studies have shown a consensus position on mucin expression profiles in pancreatic neoplasms as follows: MUC1-positive but MUC2-negative expression in PDACs; MUC1-negative but MUC2-positive expression in intestinal-type IPMNs (dangerous type); MUC1-negative and MUC2-negative expression in gastric-type IPMNs (safe type); High MUC4 expression in PDAC patients with a poor outcome; and MUC4-positive expression in intestinal-type IPMNs. We also showed that three mucin genes (MUC1, MUC2 and MUC4) expression in cancer cell line was regulated by DNA methylation. We have developed a novel ‘methylation-specific electrophoresis (MSE)’ method to analyze the DNA methylation status of mucin genes by high sensitivity and resolution. By using the MSE method, we evaluated pancreatic juice samples from 45 patients with various pancreatic lesions. The results were compared with final diagnosis of the pancreatic lesions including IHC of mucin expression in the paired pancreatic tissues. The results indicated that the DNA methylation status of MUC1, MUC2 and MUC4 in pancreatic juice matched with the mucin expression in tissue. Analyses of the DNA methylation status of MUC1, MUC2 and MUC4 were useful for differential diagnosis of human pancreatic neoplasms, with specificity and sensitivity of 87% and 80% for PDAC; 100% and 88% for intestinal-type IPMN; and 88% and 77% for gastric-type IPMN, respectively. In conclusion, MSE analysis of human pancreatic juice may provide useful information for selection of treatment for pancreatic neoplasms. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Pathobiological Implications of Mucin (MUC) Expression in the Outcome of Small Bowel Cancer.
- Author
-
Shibahara, Hiroaki, Higashi, Michiyo, Koriyama, Chihaya, Yokoyama, Seiya, Kitazono, Iwao, Kurumiya, Yasuhiro, Narita, Michihiko, Kuze, Shingo, Kyokane, Takanori, Mita, Saburo, Arai, Toshiyuki, Kato, Takehito, Yuasa, Norihiro, Yamaguchi, Ryuzo, Kubota, Hitoshi, Suzuki, Hideaki, Baba, Satoshi, Rousseau, Karine, Batra, Surinder K., and Yonezawa, Suguru
- Subjects
MUCINS ,ENTEROCLYSIS ,GENE expression ,IMMUNOHISTOCHEMISTRY ,BIOMARKERS ,MULTIVARIATE analysis - Abstract
Mucins have been associated with survival in various cancer patients, but there have been no studies of mucins in small bowel carcinoma (SBC). In this study, we investigated the relationships between mucin expression and clinicopathologic factors in 60 SBC cases, in which expression profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6 and MUC16 in cancer and normal tissues were examined by immunohistochemistry. MUC1, MUC5AC and MUC16 expression was increased in SBC lesions compared to the normal epithelium, and expression of these mucins was related to clinicopathologic factors, as follows: MUC1 [tumor location (p = 0.019), depth (p = 0.017) and curability (p = 0.007)], MUC5AC [tumor location (p = 0.063) and lymph node metastasis (p = 0.059)], and MUC16 [venous invasion (p = 0.016) and curability (p = 0.016)]. Analysis of 58 cases with survival data revealed five factors associated with a poor prognosis: poorly-differentiated or neuroendocrine histological type (p<0.001), lymph node metastasis (p<0.001), lymphatic invasion (p = 0.026), venous invasion (p<0.001) and curative resection (p<0.001), in addition to expression of MUC1 (p = 0.042), MUC5AC (p = 0.007) and MUC16 (p<0.001). In subsequent multivariate analysis with curability as the covariate, lymph node metastasis, venous invasion, and MUC5AC and/or MUC16 expression were significantly related to the prognosis. Multivariate analysis in curative cases (n = 45) showed that SBC with MUC5AC and/or MUC16 expression had a significantly independent high hazard risk after adjusting for the effects of venous invasion (hazard ratio: 5.6, 95% confidence interval: 1.8–17). In conclusion, the study shows that a MUC5AC-positive and/or MUC16-positive status is useful as a predictor of a poor outcome in patients with SBC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Expression of MUC4 Mucin Is Observed Mainly in the Intestinal Type of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
- Author
-
Kitazono, Iwao, Higashi, Michiyo, Kitamoto, Sho, Yokoyama, Seiya, Horinouchi, Michiko, Osako, Masahiko, Shimizu, Takeshi, Tabata, Mineo, Batra, Surinder K., Goto, Masamichi, and Yonezawa, Suguru
- Published
- 2013
- Full Text
- View/download PDF
33. MUC4 and MUC1 Expression in Adenocarcinoma of the Stomach Correlates with Vessel Invasion and Lymph Node Metastasis: An Immunohistochemical Study of Early Gastric Cancer.
- Author
-
Tamura, Yukihiro, Higashi, Michiyo, Kitamoto, Sho, Yokoyama, Seiya, Osako, Masahiko, Horinouchi, Michiko, Shimizu, Takeshi, Tabata, Mineo, Batra, Surinder K., Goto, Masamichi, and Yonezawa, Suguru
- Subjects
DOWN syndrome ,HUMAN chromosome 21 ,INTELLECTUAL disabilities ,PHENOTYPES ,GENE expression ,GENETIC transcription - Abstract
We have previously reported that MUC4 expression is a poor prognostic factor in various carcinomas. Our previous study also showed that MUC1 expression in gastric cancers, including the early and advanced stages is a poor prognostic factor. In the present study, the expression profiles of MUC4 and MUC1 were examined by immunohistochemistry (IHC) using two anti-MUC4 monoclonal antibodies (MAbs), 8G7 and 1G8, and anti-MUC1 MAb DF3 in 104 gastrectomy specimens of early gastric adenocarcinoma with submucosal invasion (pT1b2), including 197 histological subtype lesions. Before the IHC study of the human specimens, we evaluated the specificity of the two MAbs by Western blotting and IHC of two MUC4 mRNA expressing gastric cancer cell lines. MAb 8G7 reacted clearly, whereas MAb 1G8 did not show any reactivity, in either Western blotting or IHC. In the IHC of the gastric cancers, the expression rates of MUC4/8G7 detected by MAb 8G7, MUC4/ 1G8 detected by MAb 1G8 and MUC1/DF3 detected by MAb DF3 in well differentiated types (70%, 38/54; 67%, 36/54; 52%, 28/54) were significantly higher than those in poorly differentiated types (18%, 10/55; 36%, 20/55; 13%, 7/55) (P<0.0001; P = 0.0021; P,0.0001), respectively. The MUC4/8G7 expression was related with lymphatic invasion (r = 0.304, P = 0.033). On the other hand, the MUC4/1G8 expression was related with lymphatic invasion (r = 0.395, P = 0.001) and lymph node metastasis (r = 0.296, P = 0.045). The MUC1/DF3 expression was related with lymphatic invasion (r = 0.357, P = 0.032) and venous invasion (r = 0.377, P = 0.024). In conclusion, the expression of MUC4 as well as MUC1 in early gastric cancers is a useful marker to predict poor prognostic factors related with vessel invasion. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Expression of MUC17 Is Regulated by HIF1α-Mediated Hypoxic Responses and Requires a Methylation-Free Hypoxia Responsible Element in Pancreatic Cancer.
- Author
-
Kitamoto, Sho, Yokoyama, Seiya, Higashi, Michiyo, Yamada, Norishige, Matsubara, Shyuichiro, Takao, Sonshin, Batra, Surinder K., Yonezawa, Suguru, and Shankar, Sharmila
- Subjects
- *
GLYCOPROTEINS , *ALIMENTARY canal , *HYPOXEMIA , *METHYLATION , *PANCREATIC cancer , *PANCREATIC duct , *CANCER - Abstract
MUC17 is a type 1 membrane-bound glycoprotein that is mainly expressed in the digestive tract. Recent studies have demonstrated that the aberrant overexpression of MUC17 is correlated with the malignant potential of pancreatic ductal adenocarcinomas (PDACs); however, the exact regulatory mechanism of MUC17 expression has yet to be identified. Here, we provide the first report of the MUC17 regulatory mechanism under hypoxia, an essential feature of the tumor microenvironment and a driving force of cancer progression. Our data revealed that MUC17 was significantly induced by hypoxic stimulation through a hypoxia-inducible factor 1α (HIF1α)-dependent pathway in some pancreatic cancer cells (e.g., AsPC1), whereas other pancreatic cancer cells (e.g., BxPC3) exhibited little response to hypoxia. Interestingly, these lowresponsive cells have highly methylated CpG motifs within the hypoxia responsive element (HRE, 5'-RCGTG-3'), a binding site for HIF1α. Thus, we investigated the demethylation effects of CpG at HRE on the hypoxic induction of MUC17. Treatment of low-responsive cells with 5-aza-2'-deoxycytidine followed by additional hypoxic incubation resulted in the restoration of hypoxic MUC17 induction. Furthermore, DNA methylation of HRE in pancreatic tissues from patients with PDACs showed higher hypomethylation status as compared to those from non-cancerous tissues, and hypomethylation was also correlated with MUC17 mRNA expression. Taken together, these findings suggested that the HIF1α-mediated hypoxic signal pathway contributes to MUC17 expression, and DNA methylation of HRE could be a determinant of the hypoxic inducibility of MUC17 in pancreatic cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
35. Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type.
- Author
-
Higashi, Michiyo, Yamada, Norishige, Yokoyama, Seiya, Kitamoto, Sho, Tabata, Kazuhiro, Koriyama, Chihaya, Batra, Surinder K., and Yonezawa, Suguru
- Published
- 2012
- Full Text
- View/download PDF
36. Improved method for immunostaining of mucin separated by supported molecular matrix electrophoresis by optimizing the matrix composition and fixation procedure.
- Author
-
Matsuno, Yu-Ki, Dong, Weijie, Yokoyama, Seiya, Yonezawa, Suguru, Saito, Takuro, Gotoh, Mitsukazu, Narimatsu, Hisashi, and Kameyama, Akihiko
- Published
- 2011
- Full Text
- View/download PDF
37. Epigenetic regulation of mucin genes in human cancers.
- Author
-
Yamada, Norishige, Kitamoto, Sho, Yokoyama, Seiya, Hamada, Tomofumi, Goto, Masamichi, Tsutsumida, Hideaki, Higashi, Michiyo, and Yonezawa, Suguru
- Published
- 2011
- Full Text
- View/download PDF
38. The chitin-binding capability of Cy-AMP1 from cycad is essential to antifungal activity.
- Author
-
Yokoyama, Seiya, Iida, Yuto, Kawasaki, Yousuke, Minami, Yuji, Watanabe, Keiichi, and Yagi, Fumio
- Abstract
Antimicrobial peptides are important components of the host innate immune responses by exerting broad-spectrum microbicidal activity against pathogenic microbes. Cy-AMP1 found in the cycad ( Cycas revoluta) seeds has chitin-binding ability, and the chitin-binding domain was conserved in knottin-type and hevein-type antimicrobial peptides. The recombinant Cy-AMP1 was expressed in Escherichia coli and purified to study the role of chitin-binding domain. The mutants of Cy-AMP1 lost chitin-binding ability completely, and its antifungal activity was markedly decreased in comparison with native Cy-AMP1. However, the antimicrobial activities of the mutant peptides are nearly identical to that of native one. It was suggested that the chitin-binding domain plays an essential role in antifungal, but not antimicrobial, activity of Cy-AMP1. Copyright © 2009 European Peptide Society and John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
39. Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis.
- Author
-
Nakamura, Kodai, Hiyake, Naomi, Hamada, Tomofumi, Yokoyama, Seiya, Mori, Kazuki, Yamashiro, Kouta, Beppu, Mahiro, Sagara, Yasuaki, Sagara, Yoshiaki, Sugiura, Tsuyoshi, and Muzio, Lorenzo Lo
- Subjects
FISHER exact test ,MOUTH tumors ,POLYMERASE chain reaction ,SQUAMOUS cell carcinoma ,TUMOR antigens ,TUMOR markers ,PREDICTIVE tests ,RECEIVER operating characteristic curves ,REVERSE transcriptase polymerase chain reaction ,MICROARRAY technology ,MICRORNA ,DESCRIPTIVE statistics - Abstract
Simple Summary: Although early detection of oral squamous cell carcinoma (OSCC) is considered vital, classical biomarkers have shown poor sensitivity and specificity for early detection and monitoring of OSCC. Therefore, identification of reliable and sensitive biomarkers allowing for early detection and monitoring of OSCC is of the utmost importance. In this study, we successfully identified significantly upregulated or downregulated microRNAs in OSCC patients, and reported that a combination of six microRNAs could distinguish between OSCC and the control group with a higher degree of accuracy. Furthermore, compared with serum squamous cell carcinoma (SCC) antigen, the miRNA panel reflected the presence of OSCC accurately. The present results suggest that the combined microRNA panel based on serum microRNA levels shows potential as a novel diagnostic biomarker of OSCC. A lack of reliable biomarkers for oral squamous cell carcinoma (OSCC) poses a major clinical issue. The sensitivity and specificity of classical serum tumor markers, such as the squamous cell carcinoma antigen (SCC-Ag), are quite poor, especially for early detection. This study aimed to identify specific serum miRNAs potentially serving as OSCC biomarkers. The expression levels of candidate miRNAs in serum samples from 40 OSCC patients and 40 healthy controls were quantitatively analyzed via microarray and reverse transcription PCR (RT-PCR) analyses. To enhance the accuracy of detection, we used Fisher's linear discriminant analysis to establish a diagnostic model that incorporated a combination of selected miRNAs. Consequently, miR-19a and miR-20a were significantly upregulated in the patient group (p = 0.014 and 0.036, respectively), whereas miR-5100 was downregulated (p = 0.001). We found that a combination of six miRNAs (miR-24, miR-20a, miR-122, miR-150, miR-4419a, and miR-5100) could distinguish between OSCC and the control group with a higher degree of accuracy (Area Under the Curve, AUC: 0.844, sensitivity: 55%, and specificity: 92.5%). Furthermore, compared to serum SCC antigen, the 6-miRNA panel could accurately detect the presence of OSCC. The present specific miRNAs panel may serve as a novel candidate biomarker of oral cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Protective Effects of Peroxiredoxin 4 (PRDX4) on Cholestatic Liver Injury.
- Author
-
Zhang, Jing, Guo, Xin, Hamada, Taiji, Yokoyama, Seiya, Nakamura, Yuka, Zheng, Jianbo, Kurose, Nozomu, Ishigaki, Yasuhito, Uramoto, Hidetaka, Tanimoto, Akihide, and Yamada, Sohsuke
- Subjects
PEROXIREDOXINS ,CHOLESTASIS ,LIVER injuries ,OXIDATIVE stress ,REACTIVE oxygen species ,BILE ducts - Abstract
Accumulating evidence indicates that oxidative stress plays a critical role in initiating the progression of inflammatory and fibrotic liver diseases, including cholestatic hepatitis. Peroxiredoxin 4 (PRDX4) is a secretory antioxidase that protects against oxidative damage by scavenging reactive oxygen species (ROS) in both the intracellular compartments and extracellular space. In this study, we examined the in vivo net effects of PRDX4 overexpression in a murine model of cholestasis. To induce cholestatic liver injury, we subjected C57BL/6J wild-type (WT) or human PRDX4 (hPRDX4) transgenic (Tg) mice to sham or bile duct ligation (BDL) surgery for seven days. Our results showed that the liver necrosis area was significantly suppressed in Tg BDL mice with a reduction in the severity of liver injuries. Furthermore, PRDX4 overexpression markedly reduced local and systemic oxidative stress generated by BDL. In addition, suppression of inflammatory cell infiltration, reduced proliferation of hepatocytes and intrahepatic bile ducts, and less fibrosis were also found in the liver of Tg BDL mice, along with a reduced mortality rate after BDL surgery. Interestingly, the composition of the hepatic bile acids (BAs) was more beneficial for Tg BDL mice than for WT BDL mice, suggesting that PRDX4 overexpression may affect BA metabolism during cholestasis. These features indicate that PRDX4 plays an important role in protecting against liver injury following BDL and might be a promising therapeutic modality for cholestatic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
41. Identification of mucins by using a method involving a combination of on-membrane chemical deglycosylation and immunostaining.
- Author
-
Matsuno, Yu-ki, Dong, Weijie, Yokoyama, Seiya, Yonezawa, Suguru, Narimatsu, Hisashi, and Kameyama, Akihiko
- Subjects
- *
MUCINS , *PROTEIN analysis , *MEMBRANE proteins , *DEGLYCOSYLATION , *IMMUNOLOGICAL adjuvants , *MOLECULAR pathology , *BIOMARKERS - Abstract
Abstract: The characterization of mucins is critically important for gaining insights into the molecular pathology of diseases, including cancers, as well as for the discovery of biomarkers for disease diagnosis. However, no practical method has yet been reported for identifying mucin proteins. Here, we report a technique for immunological identification of mucins separated by supported molecular matrix electrophoresis (SMME), a recently developed membrane electrophoresis method. The technique involves on-membrane deglycosylation of mucins by using mild periodate oxidation/base-catalyzed elimination, followed by immunostaining with an antibody that specifically recognizes the mucin tandem repeat (TR) peptide. We demonstrated the method's feasibility by using MUC1 derived from 2 cancer cell lines, T47D and HPAF-II. The present method shows potential as an alternative approach for the identification of mucins separated by SMME or blotted from conventional gel electrophoresis, on a PVDF membrane. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
42. Promoter hypomethylation contributes to the expression of MUC3A in cancer cells
- Author
-
Kitamoto, Sho, Yamada, Norishige, Yokoyama, Seiya, Houjou, Izumi, Higashi, Michiyo, and Yonezawa, Suguru
- Subjects
- *
METHYLATION , *CANCER cells , *GENE expression , *CELL membranes , *GLYCOPROTEINS , *CANCER risk factors , *CANCER prognosis - Abstract
Abstract: MUC3A is a membrane-bound glycoprotein that is aberrantly expressed in carcinomas and is a risk factor for a poor prognosis. However, the exact mechanism of MUC3A expression has yet to be clarified. Here, we provide the first evidence that MUC3A gene expression is controlled by the CpG methylation status of the proximal promoter region. We show that the DNA methylation pattern is intimately correlated with MUC3A expression in breast, lung, pancreas and colon cancer cell lines. The DNA methylation status of 30CpG sites from −660 to +273 was mapped using MassARRAY analysis. MUC3A-negative cancer cell lines and those with low MUC3A expression (e.g., MCF-7) were highly methylated in the proximal promoter region, corresponding to 9CpG sites (−345 to −75bp), whereas MUC3A-positive cell lines (e.g., LS174T) had low methylation levels. Moreover, 5-aza-2′-deoxycytidine and trichostatin A treatment of MUC3A-negative cells or those with low MUC3A expression caused elevation of MUC3A mRNA. Our results suggest that DNA hypomethylation in the 5′-flanking region of the MUC3A gene plays an important role in MUC3A expression in carcinomas of various organs. An understanding of epigenetic changes in MUC3A may contribute to the diagnosis of carcinogenic risk and to prediction of outcome in patients with cancer. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
43. Methylation-Specific Electrophoresis.
- Author
-
Yokoyama S, Matsuo K, and Tanimoto A
- Subjects
- Humans, CpG Islands, Epigenesis, Genetic, DNA, DNA Methylation, Neoplasms genetics
- Abstract
Methylation of CpG sites in the promoter region of genomic DNA is an important epigenetic modification that plays a critical role in gene regulation, particularly in gene silencing. Epigenetic abnormalities, along with genetic alterations, are implicated in carcinogenesis and cancer progression. Numerous studies have investigated the role of epigenetics in cancer using various tools to assess DNA methylation. However, conventional analysis methods for DNA methylation require a large amount of DNA but lack higher sensitivity, making them unsuitable for analysis of samples with high heterogeneity, such as tumor tissues. In this study, we introduce a novel electrophoresis method named "methylation-specific electrophoresis (MSE)," which utilizes a denaturing gradient acrylamide gel. We demonstrate the applicability of the MSE method for DNA methylation analysis of the mucin gene as an example., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
44. Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to the POLE Mutation-subtype in Endometrial Cancer.
- Author
-
Kitazono I, Akahane T, Yokoyama S, Kubota E, Nishida-Kirita Y, Noguchi H, Murakami M, Yanazume S, Kobayashi H, and Tanimoto A
- Subjects
- Female, Humans, Cervix Uteri pathology, Endometrium pathology, Immunohistochemistry, Mutation, DNA Polymerase II genetics, Poly-ADP-Ribose Binding Proteins genetics, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology
- Abstract
Background/aim: Among the four genomic subtypes of endometrial cancer, distinguishing between the DNA polymerase epsilon mutation (POLEmut) and no specific molecular profile (NSMP) subtypes requires genomic profiling owing to the lack of surrogate immunohistochemical markers. We have previously found that, histologically, the POLEmut-subtype exhibits surface epithelial slackening (SES). Therefore, to improve subtype identification, we aimed to extract cytological features corresponding to SES in POLEmut-subtype cervical cytology specimens., Materials and Methods: We analyzed 104 endometrial cancer cervical cytology specimens, with integrative diagnosis confirmation via histology, immunohistochemistry, and genomic profiling. Cytological features were evaluated for the presence of atypical glandular cells, atypical cell appearance in single cells and clusters, and cytological SES and the presence of tumor-infiltrating inflammatory cells in clusters., Results: Based on cervical cytology, the POLEmut- and p53mut-subtypes exhibited more frequent atypical cells in smaller clusters, giant tumor cells, and cytological SES patterns than the NSMP-subtype. Tumor-infiltrating lymphocytes were frequent in the POLEmut- and mismatch repair-deficient subtypes., Conclusion: Histologically-detected SES as well as other endometrial cancer features may be preserved in the atypical cell clusters observed in cervical cytology specimens. Cytological detection of SES and of smaller clusters of atypical cells and inflammatory cells with moderate atypia are suggestive of POLEmut-subtype. Integrative diagnosis including genomic profiling remains critical for diagnostic confirmation., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Genome Editing Using Cas9 Ribonucleoprotein Is Effective for Introducing PDGFRA Variant in Cultured Human Glioblastoma Cell Lines.
- Author
-
Hamada T, Yokoyama S, Akahane T, Matsuo K, and Tanimoto A
- Subjects
- Humans, CRISPR-Cas Systems genetics, Ribonucleoproteins genetics, Ribonucleoproteins metabolism, Cell Line, Nucleotides metabolism, Gene Editing methods, Glioblastoma genetics
- Abstract
Many variants of uncertain significance (VUS) have been detected in clinical cancer cases using next-generation sequencing-based cancer gene panel analysis. One strategy for the elucidation of VUS is the functional analysis of cultured cancer cell lines that harbor targeted gene variants using genome editing. Genome editing is a powerful tool for creating desired gene alterations in cultured cancer cell lines. However, the efficiency of genome editing varies substantially among cell lines of interest. We performed comparative studies to determine the optimal editing conditions for the introduction of platelet-derived growth factor receptor alpha ( PDGFRA ) variants in human glioblastoma multiforme (GBM) cell lines. After monitoring the copy numbers of PDGFRA and the expression level of the PDGFRα protein, four GBM cell lines (U-251 MG, KNS-42, SF126, and YKG-1 cells) were selected for the study. To compare the editing efficiency in these GBM cell lines, the modes of clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) delivery (plasmid vs. ribonucleoprotein (RNP)), methods of transfection (lipofection vs. electroporation), and usefulness of cell sorting were then evaluated. Herein, we demonstrated that electroporation-mediated transfer of Cas9 with single-guide RNA (Cas9 RNP complex) could sufficiently edit a target nucleotide substitution, irrespective of cell sorting. As the Cas9 RNP complex method showed a higher editing efficiency than the Cas9 plasmid lipofection method, it was the optimal method for single-nucleotide editing in human GBM cell lines under our experimental conditions.
- Published
- 2022
- Full Text
- View/download PDF
46. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
- Author
-
Higa N, Akahane T, Yokoyama S, Yonezawa H, Uchida H, Fujio S, Kirishima M, Takigawa K, Hata N, Toh K, Yamamoto J, Hanaya R, Tanimoto A, and Yoshimoto K
- Subjects
- ErbB Receptors, Genetic Profile, Homozygote, Humans, Isocitrate Dehydrogenase genetics, Japan, Molecular Biology, Mutation, Prognosis, Sequence Deletion, Astrocytoma pathology, Brain Neoplasms pathology, Glioma pathology
- Abstract
Rapid technological advances in molecular biology, including next-generation sequencing, have identified key genetic alterations in central nervous system (CNS) tumors. Accordingly, the fifth edition of the World Health Organization (WHO) CNS tumor classification was published in 2021. We analyzed 303 patients with diffuse glioma using an amplicon-based glioma-tailored gene panel for detecting 1p/19q codeletion and driver gene mutations such as IDH1/2, TERTp, EGFR, and CDKN2A/B on a single platform. Within glioblastomas (GBMs), the most commonly mutated genes were TERTp, TP53, PTEN, NF1, and PDGFRA, which was the most frequently mutated tyrosine kinase receptor in GBM, followed by EGFR. The genes that most commonly showed evidence of loss were PTEN, CDKN2A/B, and RB1, whereas the genes that most commonly showed evidence of gain/amplification were EGFR, PDGFRA, and CDK4. In 22 grade III oligodendroglial tumors, 3 (14%) patients had CDKN2A/B homozygous deletion, and 4 (18%) patients had ARID1A mutation. In grade III oligodendroglial tumors, an ARID1A mutation was associated with worse progression-free survival. Reclassification based on the WHO 2021 classification resulted in 62.5% of grade II/III isocitrate dehydrogenase (IDH) -wildtype astrocytomas being classified as IDH-wildtype GBM and 37.5% as not elsewhere classified. In summary, our glioma-tailored gene panel was applicable for molecular diagnosis in the WHO 2021 classification. In addition, we successfully reclassified the 303 diffuse glioma cases based on the WHO 2021 classification and clarified the genetic profile of diffuse gliomas in the Japanese population.
- Published
- 2022
- Full Text
- View/download PDF
47. Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma.
- Author
-
Higa N, Akahane T, Yokoyama S, Yonezawa H, Uchida H, Takajo T, Otsuji R, Hamada T, Matsuo K, Kirishima M, Hata N, Hanaya R, Tanimoto A, and Yoshimoto K
- Abstract
Background: Platelet-derived growth factor receptor alpha ( PDGFRA ) is the second most frequently mutated tyrosine kinase receptor in glioblastoma (GBM). However, the prognostic impact of PDGFRA amplification on GBM patients remains unclear. Herein, we evaluated this impact by retrospectively analyzing outcomes of patients with IDH wild-type GBM., Methods: Using a custom-made oncopanel, we evaluated PDGFRA gain/amplification in 107 GBM samples harboring wild-type IDH , along with MGMT promoter ( MGMTp ) methylation status., Results: We detected PDGFRA gain/amplification in 31 samples (29.0%). PDGFRA gain/amplification predicted poor prognosis ( P = .003). Compared to unamplified PDGFRA , PDGFRA gain/amplification in GBM was associated with higher patient age ( P = .031), higher Ki-67 score ( P = .019), and lower extent of surgical resection ( P = .033). Unmethylated MGMTp also predicted poor prognosis ( P = .005). As PDGFRA gain/amplification and unmethylated MGMTp were independent factors for poor prognosis in multivariate analyses, we grouped GBM cases based on PDGFRA and MGMTp status: poor ( PDGFRA gain/amplification and unmethylated MGMTp ), intermediate ( PDGFRA gain/amplification or unmethylated MGMTp ), and good ( PDGFRA intact and methylated MGMTp ) prognosis. The Kaplan-Meier survival analysis indicated that these groups significantly correlated with the OS of GBM patients ( P < .001)., Conclusions: Here we report that PDGFRA gain/amplification is a predictor of poor prognosis in IDH wild-type GBM. Combining PDGFRA gain/amplification with MGMTp methylation status improves individual prognosis prediction in patients with IDH wild-type GBM., (© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2022
- Full Text
- View/download PDF
48. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
- Author
-
Kobayashi Y, Kitazono I, Akahane T, Yanazume S, Kamio M, Togami S, Nohara S, Sakamoto I, Yokoyama S, Tabata K, Kobayashi H, and Tanimoto A
- Subjects
- Aged, Aged, 80 and over, Carcinoma genetics, Carcinoma pathology, Carcinosarcoma genetics, Carcinosarcoma pathology, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, High-Throughput Nucleotide Sequencing, Humans, Middle Aged, Sequence Analysis, DNA, Carcinoma classification, Carcinosarcoma classification, Endometrial Neoplasms classification
- Abstract
It is often difficult to histologically differentiate among endometrial dedifferentiated carcinoma (DC), endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma (CS) due to the presence of solid components. In this study, we aimed to categorize these carcinomas according to The Cancer Genome Atlas (TCGA) classification using a small custom-made cancer genome panel (56 genes and 17 microsatellite regions) for integrated molecular diagnosis. A total of 36 endometrial cancer cases with solid components were assessed using IHC, next-generation sequencing (NGS), and the custom-made panel. Among 19 EC cases, six were categorized as MMR-deficient (MMR-d) and eight were classified as having a nonspecific molecular profile. Three EC cases were classified as POLE mutation ( POLE mut)-type, which had a very high tumor mutation burden (TMB) and low microsatellite instability (MSI). Increased TMB and MSI were observed in all three DC cases, classified as MMR-d with mutations in MLH1 and POLD1 . Except for one case classified as MMR-d, all SC cases exhibited TP53 mutations and were classified as p53 mutation-type. SC cases also exhibited amplification of CCND1 , CCNE1 , and MYC . CS cases were classified as three TCGA types other than the POLE mut-type. The IHC results for p53 and ARID1A were almost consistent with their mutation status. NGS analysis using a small panel enables categorization of endometrial cancers with solid proliferation according to TCGA classification. As TCGA molecular classification does not consider histological findings, an integrated analytical procedure including IHC and NGS may be a practical diagnostic tool for endometrial cancers., Competing Interests: SN and IS are employed by Mitsubishi Space Software. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Kobayashi, Kitazono, Akahane, Yanazume, Kamio, Togami, Nohara, Sakamoto, Yokoyama, Tabata, Kobayashi and Tanimoto.)
- Published
- 2021
- Full Text
- View/download PDF
49. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning.
- Author
-
Yokoyama S, Hamada T, Higashi M, Matsuo K, Maemura K, Kurahara H, Horinouchi M, Hiraki T, Sugimoto T, Akahane T, Yonezawa S, Kornmann M, Batra SK, Hollingsworth MA, and Tanimoto A
- Subjects
- Aged, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal metabolism, Carcinoma, Pancreatic Ductal surgery, DNA Methylation, Female, Humans, Male, Mucins genetics, Mucins metabolism, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms surgery, Prognosis, Promoter Regions, Genetic, Survival Rate, Tumor Cells, Cultured, Carcinoma, Pancreatic Ductal pathology, Machine Learning, Pancreatic Neoplasms pathology
- Abstract
Purpose: Pancreatic cancer remains a disease of high mortality despite advanced diagnostic techniques. Mucins (MUC) play crucial roles in carcinogenesis and tumor invasion in pancreatic cancers. MUC1 and MUC4 expression are related to the aggressive behavior of human neoplasms and a poor patient outcome. In contrast, MUC2 is a tumor suppressor, and we have previously reported that MUC2 is a favorable prognostic factor in pancreatic neoplasia. This study investigates whether the methylation status of three mucin genes from postoperative tissue specimens from patients with pancreatic neoplasms could serve as a predictive biomarker for outcome after surgery., Experimental Design: We evaluated the methylation status of MUC1, MUC2, and MUC4 promoter regions in pancreatic tissue samples from 191 patients with various pancreatic lesions using methylation-specific electrophoresis. Then, integrating these results and clinicopathologic features, we used support vector machine-, neural network-, and multinomial-based methods to develop a prognostic classifier., Results: Significant differences were identified between the positive- and negative-prediction classifiers of patients in 5-year overall survival (OS) in the cross-validation test. Multivariate analysis revealed that these prognostic classifiers were independent prognostic factors analyzed by not only neoplastic tissues but also nonneoplastic tissues. These classifiers had higher predictive accuracy for OS than tumor size, lymph node metastasis, distant metastasis, and age and can complement the prognostic value of the TNM staging system., Conclusions: Analysis of epigenetic changes in mucin genes may be of diagnostic utility and one of the prognostic predictors for patients with pancreatic ductal adenocarcinoma., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
50. PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.
- Author
-
Honjo K, Hamada T, Yoshimura T, Yokoyama S, Yamada S, Tan YQ, Leung LK, Nakamura N, Ohi Y, Higashi M, and Tanimoto A
- Abstract
The Purkinje cell protein 4/peptide 19 (PCP4/PEP19) is a novel breast cancer cell expressing peptide, originally found in the neural cells as an anti-apoptotic factor, could inhibit cell apoptosis and enhance cell migration and invasion in human breast cancer cell lines. The expression of PCP4/PEP19 is induced by estrogens in estrogen receptor-positive (ER
+ ) MCF-7 cells but also highly expressed in ER- SK-BR-3 cells. In this study, we investigated the effects of PCP4/PEP19 on aromatase gene expression in MCF-7 and SK-BR-3 human breast cancer cells. In SK-BR-3 cells but not in MCF-7 cells, PCP4/PEP19 knockdown by siRNA silencing decreased the aromatase expression in gene transcriptional level. When PCP4/PEP19 was overexpressed by CMV promoter-driven PCP4/PEP19 expressing plasmid transfection, aromatase gene transcription increased in SK-BR-3 cells. This aromatase gene transcription is mainly mediated through promoter region PI.1, which is usually active in the placental tissue but not in the breast cancer tissue. These results indicate a new function of PCP4/PEP19 that would enhance aromatase gene upregulation to supply estrogens in heterogeneous cancer microenvironment., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.